Cancer Research and Treatment

Mi-Ryeong Ryu

3 Articles

Prognostic Significance of Serum Carcinoembryonic Antigen Normalization on Survival in Rectal Cancer Treated with Preoperative Chemoradiation: Mi-Joo Chung, Su-Mi Chung, Ji-Yoon Kim, Mi-Ryeong Ryu; Cancer Res Treat. 2013;45(3):186-192. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.186

PURPOSE
The purpose of this retrospective study was to identify factors predictive of survival in rectal cancer patients who received surgery with curative intent after preoperative chemoradiotherapy (CRT).
MATERIALS AND METHODS
Between July 1996 and June 2010, 104 patients underwent surgery for rectal cancer after preoperative CRT. The median dose of radiotherapy was 50.4 Gy (range, 43.2 to 54.4 Gy) for 6 weeks. Chemotherapy was a bolus injection of 5-fluorouracil and leucovorin for the first and last week of radiotherapy (n=84, 77.1%) or capecitabine administered daily during radiotherapy (n=17, 16.3%). Low anterior resection (n=86, 82.7%) or abdominoperineal resection (n=18, 17.3%) was performed at a median 47 days from the end of radiotherapy, and four cycles of adjuvant chemotherapy was administered. The serum carcinoembryonic antigen (CEA) level was checked at initial diagnosis and just before surgery.
RESULTS
After a median follow-up of 48 months (range, 9 to 174 months), 5-year disease free survival (DFS) was 74.5% and 5-year overall survival (OS) was 86.4%. Down staging of T diagnoses occurred in 32 patients (30.8%) and of N diagnoses in 40 patients (38.5%). The CEA change from initial diagnosis to pre-surgery (high-high vs. high-normal vs. normal-normal) was a statistically significant prognostic factor for DFS (p=0.012), OS (p=0.002), and distant metastasis free survival (p=0.018) in a multivariate analysis.
CONCLUSION
Patients who achieve normal CEA level by the time of surgery have a more favorable outcome than those who retain a high CEA level after preoperative CRT. The normalization of CEA levels can provide important information about the prognosis in rectal cancer treatment.

Citations

Citations to this article as recorded by

Adenocarcinoma of the colon in children with LAL: A case report
Siham Abbaoui, Najlae Zaari, Abdelouhab Ammor, Houssain Benhaddou
International Journal of Surgery Case Reports.2024; 121: 109995. CrossRef
Comparison of pathological response of standard chemoradiotherapy versus short course radiotherapy in rectal carcinoma: A pilot study
Bangalore Rammohan Nagarjun, Ashini Shah, Amisha Gami, Jahnavi Gandhi, Ankita Parikh, Viraj Modi
Indian Journal of Pathology and Microbiology.2023; 66(4): 708. CrossRef
Can normalized carcinoembryonic antigen following neoadjuvant chemoradiation predict tumour recurrence after curative resection for locally advanced rectal cancer?
Youngki Hong, Amandeep Ghuman, Keat Seong Poh, Dimitri Krizzuk, Arun Nagarajan, Sudha Amarnath, Juan J. Nogueras, Steven D. Wexner, Giovanna DaSilva
Colorectal Disease.2021; 23(6): 1346. CrossRef
Prognostic Impact of Carcinoembryonic Antigen Levels in Rectal Cancer Patients Who Had Received Neoadjuvant Chemoradiotherapy
Jung Il Joo, Sang Woo Lim, Bo Young Oh
Annals of Coloproctology.2021; 37(3): 179. CrossRef
Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer
Yu-Han Lin, Chen-Hsuan Wu, Hung-Chun Fu, Yu-Jen Chen, Yin-Yi Chen, Yu-Che Ou, Hao Lin
Cancer Biomarkers.2020; 28(3): 285. CrossRef
Changes of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy
Peter Jo, Azadeh Azizian, Junius Salendo, Frank Kramer, Markus Bernhardt, Hendrik Wolff, Jens Gruber, Marian Grade, Tim Beißbarth, B. Ghadimi, Jochen Gaedcke
International Journal of Molecular Sciences.2017; 18(6): 1140. CrossRef
Two case reports
Chang hoon Ahn, Soon Chul Kim
Medicine.2017; 96(46): e8074. CrossRef
Evaluating the Prognostic Role of Elevated Preoperative Carcinoembryonic Antigen Levels in Colon Cancer Patients: Results from the National Cancer Database
Adan Z. Becerra, Christian P. Probst, Mohamedtaki A. Tejani, Christopher T. Aquina, Maynor G. González, Bradley J. Hensley, Katia Noyes, John R. Monson, Fergal J. Fleming
Annals of Surgical Oncology.2016; 23(5): 1554. CrossRef
Prognosis Can Be Predicted More Accurately Using Pre- and Postchemoradiotherapy Carcinoembryonic Antigen Levels Compared to Only Prechemoradiotherapy Carcinoembryonic Antigen Level in Locally Advanced Rectal Cancer Patients Who Received Neoadjuvant Chemor
SooYoon Sung, Seok Hyun Son, Chul Seung Kay, Yoon Suk Lee
Medicine.2016; 95(10): e2965. CrossRef
Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study
Mi Joo Chung, Taek Keun Nam, Jae Uk Jeong, Sung Hwan Kim, Kyubo Kim, Hong Seok Jang, Bae Kwon Jeong, Jong Hoon Lee
International Journal of Colorectal Disease.2016; 31(9): 1595. CrossRef
Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis
Songmi Jeong, Taek Keun Nam, Jae Uk Jeong, Sung Hwan Kim, Kyubo Kim, Hong Seok Jang, Bae Kwon Jeong, Jong Hoon Lee
Clinical & Experimental Metastasis.2016; 33(8): 809. CrossRef
Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
Chiara Molinari, Federica Matteucci, Paola Caroli, Alessandro Passardi
Clinical Colorectal Cancer.2015; 14(4): 227. CrossRef
Desenlaces del manejo no quirúrgico posterior a neoadyuvancia del cáncer localmente avanzado de recto
Pilar Adriana Torres-Mesa, Ricardo Oliveros, Jorge Mesa, Natalia Olaya, Ricardo Sánchez
Revista Colombiana de Cancerología.2014; 18(3): 109. CrossRef

12,595 View
68 Download
13 Crossref

Clinical Experience of Patients with Ductal Carcinoma In Situ of the Breast Treated with Breast-Conserving Surgery plus Radiotherapy: A Preliminary Report: Ji-Young Jang, Mi-Ryeong Ryu, Sung-Whan Kim, Chul-Seung Kay, Yeon-Sil Kim, Yoon-Kyeong Oh, Hyung-Chul Kwon, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung; Cancer Res Treat. 2005;37(6):344-348. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.344

Abstract PDF PubReader ePub: Purpose
Breast-conserving therapy (BCT) is a practical alternative to mastectomy for treating ductal carcinoma in situ (DCIS). We reviewed our experience for treating patients with DCIS of the breast to evaluate the outcome after performing breast-conserving surgery plus radiotherapy (BCS-RT).
Materials and Methods
Between January 1983 and December 2002, 25 patients with clinically or mammographically detected DCIS were treated by BCS-RT. One patient was diagnosed with bilateral DCIS. Thirteen cases (50%) had symptomatic lesions at presentation. All 26 cases of 25 patients underwent BCS such as lumpectomy, partial mastectomy or quadrantectomy. All of them received whole breast irradiation to a median dose of 50.4 Gy. Twenty-four cases (92.3%) received a boost to the tumor bed for a median total dose of 59.4 Gy. The median follow up period was 67 months (range: 38 to 149 months).
Results
Two cases (7.7%) experienced ipsilateral breast tumor recurrence (IBTR) after BCS-RT. The histology results at the time of IBTR showed invasive ductal carcinoma (IDC), and the median time to IBTR was 25.5 months. On the univariate analysis, there were no significant factors associated with IBTR in the DCIS patients. The three-year local recurrence free survival rate was 96.0% and the overall survival rate was 96.3%.
Conclusion
After the treatment for DCIS, the IBTR rate in our study was similar to other previous studies. Considering that we included patients who had many symptomatic lesions, close or positive margins and less that complete early data, our result is comparable to the previous studies. We could not find the prognostic significant factors associated with IBTR after BCS-RT. A longer follow up period with more patients would be required to evaluate the role of any predictive factors and to confirm these short-term results.

8,314 View
56 Download

The Role of Radiation Therapy for the Extramammary Paget's Disease of the Vulva ; Experience of 3 Cases: Seok-Hyun Son, Jung-Seok Lee, Yeon-Sil Kim, Mi-Ryeong Ryu, Su-Mi Chung, Sung-Eun Namkoong, Gu-Taek Han, Hee-Jeong Lee, Sei-Chul Yoon; Cancer Res Treat. 2005;37(6):365-369. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.365

Abstract PDF PubReader ePub

We have experienced three cases of extramammary Paget's disease (EMPD) of the vulva that received radiation therapy (RT). Here, we analyze the efficacy of RT and include a literature survey.

Three patients with EMPD of the vulva were treated with curative RT between 1993 and 1998. One of the patients had associated underlying adenocarcinoma of the vulva. The total doses of radiation administered were 54~78 Gy/6~8 weeks. Radiation fields encompassed 2 to 3 cm outer margins free from all visible disease including or not including the inguinal area using a 9 MeV electron or a 6 MV photon beam. Follow-up durations after radiotherapy were 0.6~11 years. Complete response was obtained in all three patients. Marginal failure occurred in one patient, and another patient with underlying adenocarcinoma treated by vulvectomy with bilateral inguinal lymph node dissection followed by external RT showed no relapse. Radiation induced side effects were transient acute confluent wet desquamation in the treated area resulting in mild late atrophic skin changes.

Although surgery is currently considered the preferred primary treatment for EMPD, it has a high relapse rate due to the multifocal nature of the disease. We conclude that RT is of benefit in some selected cases of EMPD.

Citations

Citations to this article as recorded by

Anatomic Subtype Differences in Extramammary Paget Disease
Nour Kibbi, Joshua L. Owen, Brandon Worley, Jake X. Wang, Vishnu Harikumar, Sumaira Z. Aasi, Sunandana Chandra, Jennifer N. Choi, Yasuhiro Fujisawa, Christos Iavazzo, John Y. S. Kim, Naomi Lawrence, Mario M. Leitao, Allan B. MacLean, Jeffrey S. Ross, Anth
JAMA Dermatology.2024; 160(4): 417. CrossRef
Vulvar Paget Disease: a series of cases in southern Brazil
Marcella B. Persiano, Elisa T. Rosin, Giovana A. Cabrera, Fernanda Uratani, Leticia V. Pires, Felipe Luzzatto, Kathleen M. Schmeler, Mila P. Salcedo
Journal of Global Health Reports.2023;[Epub] CrossRef
The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease
Michelle van der Linden, Colette L. van Hees, Marc van Beurden, Johan Bulten, Eleonora B. van Dorst, Martha D. Esajas, Kim A. Meeuwis, Dorry Boll, Mariëtte I. van Poelgeest, Joanne A. de Hullu
American Journal of Obstetrics and Gynecology.2022; 227(2): 250.e1. CrossRef
Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget’s Disease of the Vulva
Marina Stasenko, Gowtham Jayakumaran, Renee Cowan, Vance Broach, Dennis S. Chi, Anthony Rossi, Travis J. Hollman, Ahmet Zehir, Nadeem R. Abu-Rustum, Mario M. Leitao
JCO Precision Oncology.2020; (4): 1054. CrossRef
Invasive Vulval Paget’s disease treated with primary radiotherapy: A rare case report and literature review
Avir Sarkar, S.C. Saha, Pooja Sikka, Neha Kumari, Pranab Dey, Bhavana Rai
Gynecologic Oncology Reports.2020; 34: 100674. CrossRef
Nonsurgical Treatments for Extramammary Paget Disease: A Systematic Review and Meta-Analysis
Igor Snast, Eran Sharon, Ran Kaftory, Yehonatan Noyman, Meital Oren-Shabtai, Moshe Lapidoth, Emmilia Hodak, Daniel Mimouni, Sigal Mazor, Assi Levi
Dermatology.2020; 236(6): 493. CrossRef
A Rare Case of Recurrent Paget’s Disease of the Vulva and Gluteal Region Treated with Radiation Therapy
Mirza Athar Ali, M. Babaiah, Prabhakar Mariappan, Sudha Sinha, KR Muralidhar, Srinivas Ponaganti, Pranav Ashwin Shah, Sujana Priya Vuba, Arun Kumar Reddy Gorla, Deepak Koppaka
Applied Radiation Oncology.2020; : 44. CrossRef
Efficacy of low‐dose 5‐fluorouracil/cisplatin therapy for invasive extramammary Paget's disease
Hiroshi Kato, Shoichi Watanabe, Kiyonori Kariya, Motoki NAKAMURA, Akimichi Morita
The Journal of Dermatology.2018; 45(5): 560. CrossRef
The Role of Radiotherapy in Extramammary Paget Disease: A Systematic Review
L. Tagliaferri, C. Casà, G. Macchia, A. Pesce, G. Garganese, B. Gui, G. Perotti, S. Gentileschi, F. Inzani, R. Autorino, S. Cammelli, A.G. Morganti, V. Valentini, M.A. Gambacorta
International Journal of Gynecologic Cancer.2018; 28(4): 829. CrossRef
The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease
Michelle van der Linden, Kim Meeuwis, Colette van Hees, Eleonora van Dorst, Johan Bulten, Tjalling Bosse, Joanna IntHout, Dorry Boll, Brigitte Slangen, Manon van Seters, Marc van Beurden, Mariëtte van Poelgeest, Joanne de Hullu
JMIR Research Protocols.2017; 6(9): e178. CrossRef
Paget disease of the vulva
M. van der Linden, K.A.P. Meeuwis, J. Bulten, T. Bosse, M.I.E. van Poelgeest, J.A. de Hullu
Critical Reviews in Oncology/Hematology.2016; 101: 60. CrossRef
Primary extramammary invasive Paget’s vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy?
Maria Tolia, Nikolaos Tsoukalas, Chrisostomos Sofoudis, Constantinos Giaginis, Despoina Spyropoulou, Dimitrios Kardamakis, Vasileios Kouloulias, George Kyrgias
BMC Cancer.2016;[Epub] CrossRef
Extramammary Paget Disease of the Vulva: Minimal Excision with Adjuvant Radiation Treatment for Optimal Aesthetic Results
Myeong Su Jeon, Gyu Yong Jung, Joon Ho Lee, Kyung Won Kang, Kwang Won No
Tumori Journal.2016; 102(2_suppl): S84. CrossRef
Paget Disease of the Vulva: Diagnosis by Immunohistochemistry
Andressa Gonçalves Amorim, Brunelle Batista Fraga Mendes, Rodrigo Neves Ferreira, Antônio Chambô Filho
Case Reports in Dermatological Medicine.2015; 2015: 1. CrossRef
Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors
M. Hata, I. Koike, H. Wada, E. Miyagi, T. Kasuya, H. Kaizu, T. Matsui, Y. Mukai, E. Ito, T. Inoue
Annals of Oncology.2014; 25(1): 291. CrossRef
Radiotherapy in Patients with Extramammary Paget's Disease - Our Own Experience and Review of the Literature
Tomohiro Itonaga, Hidetsugu Nakayama, Mitsuru Okubo, Ryuji Mikami, Sachica Nogi, Yu Tajima, Shinji Sugahara, Koichi Tokuuye
Oncology Research and Treatment.2014; 37(1-2): 18. CrossRef
Extramammary Paget's Disease of the Vulva: A Case Report and Review of the Literature
Nirmala Duhan, Mansi Juneja, Sunita Singh
Journal of Gynecologic Surgery.2013; 29(6): 297. CrossRef
HDR-plesiotherapy for the treatment of anogenital extramammary Paget's disease
Soraya Marcos, Angel Montero, Belén Capuz, Javier Martinez-Ollero, Raúl Hernanz, Eva Fernández, Alfredo Polo, Alfredo Ramos
Reports of Practical Oncology & Radiotherapy.2012; 17(3): 163. CrossRef
Extramammary Paget's disease treated with topical imiquimod 5% cream
Sue-Ann J. E. Ho, Derrick C. W. Aw
Dermatologic Therapy.2010; 23(4): 423. CrossRef

13,237 View
134 Download
19 Crossref

Author index